Real-time education makes headlines

Share this article:

Do physicians need a CNN for CME? Some vendors think so and are implementing real-time educational offerings.

“The doctor will not accept in their consumer life what they accept in their professional life: that the forest fire happened two months ago and they hear about it now for the first time,” said Bob Stern, CEO of breaking medical news site MedPage Today. “That's an unacceptable experience.”

The “rapid-distribution” model of presenting news from meetings or journals with credit is becoming more important as a way to meet physician needs, agreed Mario Nacinovich, Jr., co-founder/co-CEO, Fission Communications. Indeed, “some CME stakeholders are reconsidering the lengthy content development and production processes associated with traditional enduring materials,” he said.

That's not to say the traditional model is dead—far from it. According to a recent Pri-Med study, readership of one of its print CME newsletters rose 85% from 2005 to 2006. The study shows physicians still value print as a way to obtain information on new treatment options and therapies, Pri-Med's director of physician insights, Anne Goodrich, said.

Others making the immediacy push include vendors such as Epocrates, which disseminates scientific findings in lessons on handheld devices.

But MedPage Today is seriously embracing the daily news model. Its redesigned homepage contains about 12-15 stories displayed in a newspaper-like format and more standalone video stories. 
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...